PIP-2

**PIP-2** is the lead investigational compound developed by Peroxitech to address cytokine storm-induced respiratory failure in the lungs, a critical complication in severe inflammatory conditions such as acute respiratory distress syndrome (ARDS) regardless of underlying etiology like viral infections or sepsis. It targets the excessive buildup of pro-inflammatory cytokines that drive lung damage and hypoxemia, aiming to mitigate hyperinflammation and prevent progression to multi-organ failure. As an early-stage asset, its precise mechanism—potentially involving modulation of inflammatory signaling pathways or cytokine neutralization—remains proprietary, with development focused on unmet needs in critical care.